Select therapeutic use:
Indications for EMTRIVA:
≥18yrs: 200mg once daily. Renal impairment (CrCl 30–49mL/min): 200mg every 48hrs; (CrCl 15–29mL/min): 200mg every 72hrs; (CrCl <15mL/min or dialysis): 200mg every 96hrs.
<3 months: not recommended. 3 months–17yrs: ≤33kg: use soln form. >33kg: 200mg once daily. Renal impairment: reduce dose or prolong dosing interval (see literature).
Suspend therapy if lactic acidosis or hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Not for treating chronic hepatitis B; test for HBV before starting therapy and closely monitor patients co-infected with HBV and HIV during and for several months after stopping treatment (discontinuing therapy may exacerbate HBV infection). Women, obesity, or prolonged nucleoside exposure, other risk factors for hepatic dysfunction: increased risk of toxicity (eg, lactic acidosis). Renal impairment. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.
Avoid concomitant drugs that contain emtricitabine or lamivudine.
Nucleoside analogue (reverse transcriptase inhibitor).
Headache, GI upset, fatigue, dizziness, depression, insomnia, abnormal dreams, rash, abdominal pain, asthenia, increased cough, rhinitis; lactic acidosis, severe hepatomegaly with steatosis, fat redistribution, immune reconstitution syndrome, exacerbation of hepatitis B; also children: skin hyperpigmentation.
Register pregnant patients exposed to emtricitabine by calling (800) 258-4263.